Picture loading failed.

Anti-TNFRSF17;CD3E therapeutic antibody (Pre-made Pacanalotamab biosimilar,Bispecific scFv) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Pacanalotamab is an anti-BCMA-anti-CD3-bispecific-antibody, where the bispecific T-cell engager (BiTE) binds to the CD3 epsilon subunit of the T cell receptor complex on T-cells and to B-cell maturation antigen (BCMA), a membrane-bound receptor on plasma cells, resulting in activation of T cells against BCMA.

Order informatioin


Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-421-1mg 1mg Inquiry
GMP-Bios-ab-421-10mg 10mg Inquiry
GMP-Bios-ab-421-100mg 100mg Inquiry
GMP-Bios-ab-421-xmg >100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Anti-TNFRSF17;CD3E therapeutic antibody (Pre-made Pacanalotamab biosimilar,Bispecific scFv)
INN Name Pacanalotamab
TargetTNFRSF17;CD3E
FormatBispecific scFv
DerivationBispecific antibody
Species ReactivityHuman
CH1 Isotypena;na
VD LCKappa;Lambda
Highest_Clin_Trial (Jan '20)Phase-I
Est. StatusActive
100% SI StructureNone;None
99% SI StructureNone;None
95-98% SI StructureNone;None
Year Proposed2020
Year Recommended2021
CompaniesAmgen
Conditions Approvedna
Conditions ActiveMultiple myeloma
Conditions Discontinuedna
Development TechBiTE Technology